Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors

Open access
Kulke, Matthew H., Bergsland, Emily K., Ryan, David P., Enzinger, Peter C., Lynch, Thomas J., Zhu, Andrew X., Meyerhardt, Jeffrey A., Heymach, John V., Fogler, William E., Sidor, Carolyn, Michelini, Ann, Kinsella, Kate, Venook, Alan P., Fuchs, Charles S.·2006·Journal of Clinical Oncology

Abstract

Purpose: Endostatin is a 20-kd proteolytic fragment of collagen XVIII that, in preclinical studies, has been shown to have antiangiogenic and antitumor activity. Both preclinical and human phase I studies of recombinant human endostatin (rhEndostatin) suggested activity in neuroendocrine tumors, which are known to be hypervascular. We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors. Patients and Methods: Forty-two patients with advanced pancreatic endocrine tumors or carcinoid tumors were treated with rhEndostatin administered as a bid subcutaneous injection at a starting dose of 60 mg/m 2/d. Steady-state trough levels were obtained after 6 weeks of therapy; patients who did not achieve a target therapeutic level of 300 ng/mL underwent dose escalation to 90 mg/m 2/d. Patients were observed for evidence of toxicity, response, and survival. Results: rhEndostatin was associated with minimal toxicity. However, among 40 patients assessable for radiologic response, none experienced partial response to therapy, as defined by WHO criteria. The median steady-state trough level achieved after dose escalation was 331 ng/mL, within the postulated therapeutic range. Conclusion: Treatment with rhEndostatin did not result in significant tumor regression in patients with advanced neuroendocrine tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2006.05.6762

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 174

Metadata

Authors
Kulke, M. H., Bergsland, E. K., Ryan, D. P., Enzinger, P. C., Lynch, T. J., Zhu, A. X., Meyerhardt, J. A., Heymach, J. V., Fogler, W. E., Sidor, C., Michelini, A., Kinsella, K., Venook, A. P., & Fuchs, C. S.
Venue
Journal of Clinical Oncology
Published
2006-08-01
Volume
24
Issue
22
Pages
3555-3561
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2150478512
Cited by
174
References
3
FWCI
11.95
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors. https://app.cochat.ai/papers/10.1200/jco.2006.05.6762
The paper
Kulke, M. H., Bergsland, E. K., Ryan, D. P., Enzinger, P. C., Lynch, T. J., Zhu, A. X., Meyerhardt, J. A., Heymach, J. V., Fogler, W. E., Sidor, C., Michelini, A., Kinsella, K., Venook, A. P., & Fuchs, C. S. (2006). Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.05.6762

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.